ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Recurrence and mortality after Pseudomonas aeruginosa bloodstream infection: a population-based cohort study.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPseudomonas aeruginosa bloodstream infections pose challenges due to recurrence and mortality. Identifying these outcomes may support more targeted empiric therapy.
methodsA population-based cohort study was conducted in Queensland (2000-2019). Patients were classified into four outcomes. Multinomial (relative risk ratios [RRR]) and binary logistic regression (with odds ratio [OR]) identified baseline factors associated with recurrence and mortality.
resultsAmong 5,742 patients with P. aeruginosa BSI, 20.5% died within 30 days, 21.3% died between 30 days and three years, 4.6% experienced recurrence, and 53.6% survived to three years without recurrence. Factors associated with recurrence included malignancy (RRR 3.43; 95% CI 2.55-4.62), metastatic cancer (RRR 2.16; 95% CI 1.27-3.66), and uncomplicated diabetes (RRR 2.25; 95% CI 1.31-3.86). Mortality was associated with malignancy (OR 2.65; 95% CI 2.22-3.16), congestive heart failure (OR 1.67; 95% CI 1.38-2.04), dementia (OR 1.97; 95% CI 1.46-2.65), renal disease (OR 1.85; 95% CI 1.55-2.19), pulmonary disease (OR 1.32; 95% CI 1.08-1.62), and advancing age (OR 1.02; 95% CI 1.02-1.03). Community-onset infections and a genitourinary source were associated with a reduced risk of both recurrence (RRR 0.52; 95% CI 0.33-0.81 and RRR 0.70; 95% CI 0.43-1.14) and mortality (OR 0.68; 95% CI 0.55-0.85 and OR 0.66; 95% CI 0.52-0.84, respectively). Among patients with recurrence, resistance emerged to ceftazidime (10.7%), and ciprofloxacin (10.1%), although most susceptibility profiles remained stable.
conclusionsAmong patients with P. aeruginosa BSI, rates of mortality and clinically relevant recurrence were high. These findings may assist clinicians in making more informed empiric treatment decisions.
Indexed as
Identifiers
41460458What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.